561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation

• Maria Jure-Kunkel,
• Rachelle Kosoff,
• Mark Fereshteh,
• Alexander Muik,
• Isil Altintas,
• Friederike Gieseke,
• Kristina Schödel,
• Theodora Salcedo,
• Saskia Burm,
• Aras Toker,
• Lena Kranz,
• Mathias Vormehr,
• David Eisel,
• Özlem Türeci,
• Esther Breij,
• Tahamtan Ahmadi,
• Ugur Sahin

Affiliations

Maria Jure-Kunkel

2Genmab A/S, Utrecht, Netherlands

Rachelle Kosoff

2Genmab A/S, Utrecht, Netherlands

Mark Fereshteh

2Genmab A/S, Utrecht, Netherlands

Alexander Muik

1BioNTech SE, Mainz, Germany

Isil Altintas

2Genmab A/S, Utrecht, Netherlands

Friederike Gieseke

1BioNTech SE, Mainz, Germany

Kristina Schödel

1BioNTech SE, Mainz, Germany

Theodora Salcedo

2Genmab A/S, Utrecht, Netherlands

Saskia Burm

2Genmab A/S, Utrecht, Netherlands

Aras Toker

1BioNTech SE, Mainz, Germany

Lena Kranz

1BioNTech SE, Mainz, Germany

Mathias Vormehr

1BioNTech SE, Mainz, Germany

David Eisel

1BioNTech SE, Mainz, Germany

Özlem Türeci

1BioNTech SE, Mainz, Germany

Esther Breij

2Genmab A/S, Utrecht, Netherlands

Tahamtan Ahmadi

2Genmab A/S, Utrecht, Netherlands

Ugur Sahin

1BioNTech SE, Mainz, Germany